Cardiovascular oncology: a new discipline inside internal medicine?

详细信息    查看全文

• 作者：Domenico Prisco (1)
  Mario Milco D’Elios (1)
  Caterina Cenci (1)
  Lucia Ciucciarelli (1)
  Carlo Tamburini (1)
  
• 关键词：Cancer ; Cardiotoxicity ; Cardiovascular oncology ; Venous thromboembolism ; Internal medicine
• 刊名：Internal and Emergency Medicine
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：9
• 期：4
• 页码：359-364
• 全文大小：
• 参考文献：1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102:14-5 CrossRef
  2. Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 7:111-31 CrossRef
  3. Albini A, Donatelli F, Focaccetti C, D’Elios MM, Noonan DM (2012) Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology. Intern Emerg Med 7:399-01 CrossRef
  4. Khorana AA (2012) Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Progr 2012:626-30
  5. Hong RA, Limura T, Sumida KN, Eager RM (2010) Cardio-oncology/onco-cardiology. Clin Cardiol 33:733-37 CrossRef
  6. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-221 CrossRef
  7. Darby SC, Ewertz M, Mc Gale P, Bennet AM, Goldman UB, Bronnum D et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-98 CrossRef
  8. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agent and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 23:155-66 CrossRef
  9. Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34:1102-111 CrossRef
  10. Falciani M, Imberti D, Prisco D (2006) Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update. Intern Emerg Med 1:273-78 CrossRef
  11. Agnelli G, Verso M, Mandalà M, Gallus S, Cimminiello C, Apolone G et al (2013) A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med. doi:10.1007/s11739-013-0985-z
  12. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology practice guidelines update. J Clin Oncol 31:2189-204 CrossRef
  13. Mandalà M, Falanga A, Roila F, ESMO Guidelines Working Group (2010) Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol 21:274-76 CrossRef
  14. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Elie A et al (2012) Prevention of VTE in nonsurgical patients: American College of chest physicians evidence-based clinical practice guidelines (9th edition). Chest 14:195-26
  15. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B et al (2012) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11:56-0 CrossRef
  16. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-34 CrossRef
  17. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7:291-92 CrossRef
  18. Khorana AA (2013) Targeted prophylaxis in cancer: the evidence accumulates. Intern Emerg Med 8:187-89 CrossRef
  19. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943-49 CrossRef
  20. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M et al (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179 CrossRef
  21. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366:601-09 CrossRef
  22. Tsang JS, Naughton PA, O’Donnel J, Wang TT, Moneley DS, Kelly CJ et al (2011) Acute limb ischemia in cancer patients: should we surgically intervene? Ann Vasc Surg 25:954-60 CrossRef
  23. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-239 CrossRef
  
• 作者单位：Domenico Prisco (1)
  Mario Milco D’Elios (1)
  Caterina Cenci (1)
  Lucia Ciucciarelli (1)
  Carlo Tamburini (1)
  
  1. Department of Experimental and Clinical Medicine, University of Florence and SOD Patologia Medica, AOU Careggi, Florence, Italy
  
• ISSN：1970-9366

文摘

Cardiovascular disease and cancer incidence and prevalence have risen over the past few decades to become the leading causes of death. On the one hand, cancer patients will be treated with cardiotoxic chemotherapies; on the other, cardiovascular patients will receive a new diagnosis of cancer and will have to face treatments that may worsen their disease. Moreover, venous thromboembolism can commonly complicate the natural course of patients with cancer in an apparently spontaneous manner or can be triggered by a clinical event such as surgery, invasive procedures, a course of chemotherapy or radiotherapy and is known to be the second cause of death in these patients who also may need to be treated for pre-existing medical conditions or comorbidities. Thus, we introduce the concept of cardiovascular oncology (in the place of cardiooncology) to underline that the problems in this field are not limited to cardiotoxicity of chemotherapies and to the interaction between cardiologists and oncologists, and we focus on the role of the Internist, the only health care giver able to face the multiple problems that cancer patients may undergo.